Woodline Partners LP Purchases 56,533 Shares of Immunome, Inc. (NASDAQ:IMNM)

Woodline Partners LP raised its stake in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) by 6.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 980,925 shares of the company's stock after purchasing an additional 56,533 shares during the quarter. Woodline Partners LP owned 1.23% of Immunome worth $10,417,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of IMNM. Enavate Sciences GP LLC acquired a new position in Immunome during the 4th quarter worth $36,939,000. JPMorgan Chase & Co. boosted its stake in Immunome by 2,540.4% in the 4th quarter. JPMorgan Chase & Co. now owns 648,610 shares of the company's stock worth $6,888,000 after purchasing an additional 624,045 shares during the period. Granahan Investment Management LLC acquired a new position in Immunome in the 4th quarter worth $3,337,000. Renaissance Technologies LLC boosted its stake in shares of Immunome by 2,696.5% during the 4th quarter. Renaissance Technologies LLC now owns 316,000 shares of the company's stock worth $3,356,000 after buying an additional 304,700 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. boosted its stake in shares of Immunome by 127.3% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 500,000 shares of the company's stock worth $5,310,000 after buying an additional 280,000 shares during the last quarter. 44.58% of the stock is owned by institutional investors and hedge funds.

Immunome Stock Performance

IMNM traded up $0.41 during midday trading on Wednesday, reaching $9.01. The company had a trading volume of 160,715 shares, compared to its average volume of 916,169. The stock has a market cap of $783.72 million, a PE ratio of -1.11 and a beta of 2.00. Immunome, Inc. has a 12-month low of $5.15 and a 12-month high of $16.81. The business has a 50-day moving average price of $7.59 and a two-hundred day moving average price of $9.61.

Immunome (NASDAQ:IMNM - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.52) EPS for the quarter, beating analysts' consensus estimates of ($0.66) by $0.14. The company had revenue of $2.93 million for the quarter, compared to analysts' expectations of $0.46 million. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. On average, research analysts anticipate that Immunome, Inc. will post -2.21 earnings per share for the current year.

Insider Activity at Immunome

In other Immunome news, CEO Clay B. Siegall purchased 137,100 shares of the company's stock in a transaction that occurred on Wednesday, March 26th. The shares were bought at an average cost of $7.29 per share, for a total transaction of $999,459.00. Following the purchase, the chief executive officer now owns 806,736 shares of the company's stock, valued at $5,881,105.44. This represents a 20.47% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CTO Philip Tsai purchased 12,300 shares of the company's stock in a transaction that occurred on Monday, March 24th. The shares were acquired at an average price of $8.42 per share, for a total transaction of $103,566.00. Following the completion of the purchase, the chief technology officer now directly owns 33,300 shares in the company, valued at $280,386. This represents a 58.57% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 156,400 shares of company stock worth $1,160,495. 8.60% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts recently issued reports on IMNM shares. Lake Street Capital began coverage on shares of Immunome in a research note on Wednesday, April 2nd. They issued a "buy" rating and a $23.00 target price for the company. Guggenheim cut their target price on shares of Immunome from $35.00 to $25.00 and set a "buy" rating on the stock in a research report on Thursday, March 20th. Wall Street Zen upgraded shares of Immunome from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Stephens reaffirmed an "overweight" rating and issued a $30.00 price target on shares of Immunome in a research note on Thursday, March 20th. Finally, Lifesci Capital started coverage on shares of Immunome in a research report on Tuesday, March 11th. They set an "outperform" rating and a $20.00 target price for the company. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $23.33.

Immunome Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.